loading...| Preferred Name |
dasatinib |
|
| Synonyms |
BMS-354825 Sprycel |
|
| Definitions |
An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C38713" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38713" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000315885 |
|
| altLabel |
BMS-354825 Sprycel |
|
| cui |
C1328005 C1455147 C1723829 |
|
| DATE FIRST PUBLISHED |
2003-06-23 |
|
| Date last modified |
2012-08-30 |
|
| definition |
An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C38713" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38713" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C38713 |
|
| notation |
CDR0000315885 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
dasatinib |
|
| tui |
T109 T121 |